文献速递腹部MRCT

MRI与CT评估胰腺腺癌血管侵犯的诊断准确性比较:系统评价与Meta分析

MRI vs. CT for pancreatic adenocarcinoma vascular invasion: comparative diagnostic test accuracy systematic review and meta-analysis.
PubMed 文献 · Eur Radiol · 2023-04-21

该系统评价比较MRI与胰腺协议CT评估胰腺导管腺癌血管侵犯的诊断准确性,检索至2021年12月,纳入3项研究共107例患者474根无血管侵犯和65根有血管侵犯的血管。MRI与CT的敏感度分别为71%和74%,特异度均为97%,差异无统计学意义(p=0.81和0.73)。基于有限数据,MRI可能在某些患者中作为胰腺协议CT的合适替代,尤其已行单期CT者。

要点

  • MRI与胰腺协议CT诊断胰腺导管腺癌血管侵犯的敏感度和特异度无显著差异。
  • MRI敏感度71%(95%CI 47-87%),CT敏感度74%(95%CI 56-86%),特异度均为97%。
  • 作者认为MRI可能在某些患者中替代胰腺协议CT,尤其是已行单期CT者。

核心结论

  • 基于有限数据,MRI与胰腺协议CT评估胰腺导管腺癌血管侵犯无差异;MRI可能在某些患者中作为胰腺协议CT的合适替代,尤其已行单期CT者;需要更大规模、低偏倚风险、纳入新辅助治疗患者的更新队列研究。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、EMBASE、Cochrane Central和Scopus至2021年12月,纳入3项在同一患者中比较MRI与CT诊断经病理确诊胰腺导管腺癌血管侵犯的诊断准确性研究,共107例患者474根无血管侵犯和65根有血管侵犯的血管;以切除或剖腹探查所见为首选参考标准;由两位作者使用QUADAS-C工具进行数据提取、偏倚风险和适用性评估;采用双变量随机效应Meta分析和Meta回归,报告95%CI。

诊断标准与关键数值

  • MRI诊断胰腺导管腺癌血管侵犯的敏感度71%(95%CI 47-87%),CT敏感度74%(95%CI 56-86%);MRI特异度97%(95%CI 94-99%),CT特异度97%(95%CI 94-98%);MRI与CT敏感度比较p=0.81,特异度比较p=0.73。

临床应用与阅片要点

  • 作者认为MRI可能在某些患者中作为胰腺协议CT的合适替代,尤其已行单期CT者;所有患者分期前未接受新辅助治疗。

局限性

  • 仅纳入3项研究,数据有限。
  • 存在选择偏倚:仅一部分CT患者接受了MRI。
  • 存在验证偏倚:不可切除疾病患者未经手术确认。
  • 需要更大规模、更新近、低偏倚风险的队列研究,包括接受新辅助治疗的患者。
  • 需要更多直接比较MRI与CT在新辅助治疗后胰腺导管腺癌分期诊断性能的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To perform a systematic review comparing the diagnostic accuracy of MRI vs. CT for assessing pancreatic ductal adenocarcinoma (PDAC) vascular invasion.

METHODS: MEDLINE, EMBASE, Cochrane Central, and Scopus were searched until December 2021 for diagnostic accuracy studies comparing MRI vs. CT to evaluate vascular invasion of pathologically confirmed PDAC in the same patients. Findings on resection or exploratory laparotomy were the preferred reference standard. Data extraction, risk of bias, and applicability assessment were performed by two authors using the Quality Assessment of Diagnostic Accuracy Studies-Comparative Tool. Bivariate random-effects meta-analysis and meta-regression were performed with 95% confidence intervals (95% CI).

RESULTS: Three studies were included assessing 474 vessels without vascular invasion and 65 with vascular invasion in 107 patients. All patients were imaged using MRI at ≥ 1.5 T and a pancreatic protocol CT. No difference was shown between MRI and CT for diagnosing PDAC vascular invasion: MRI/CT sensitivity (95% CI) were 71% (47-87%)/74% (56-86%), and specificity were 97% (94-99%)/97% (94-98%). Sources of bias included selection bias from only a subset of CT patients undergoing MRI and verification bias from patients with unresectable disease not confirmed on surgery. No patients received neoadjuvant therapy prior to staging.

CONCLUSIONS: Based on limited data, no difference was observed between MRI and pancreatic protocol CT for PDAC vascular invasion assessment. MRI may be an adequate substitute for pancreatic protocol CT in some patients, particularly those who have already had a single-phase CT. Larger and more recent cohort studies at low risk of bias, including patients who have received neoadjuvant therapy, are needed.

CLINICAL RELEVANCE STATEMENT: Abdominal MRI performed similarly to pancreatic protocol CT at assessing pancreatic ductal adenocarcinoma vascular invasion, suggesting local staging is adequate in some patients using MRI. More data are needed using larger, more recent cohorts including patients with neoadjuvant treatment.

KEY POINTS: • Based on limited data, no difference was found between MRI and pancreatic protocol CT sensitivity and specificity for diagnosing PDAC vascular invasion (p = 0.81, 0.73 respectively). • Risk of bias could be reduced in future PDAC MRI vs CT comparative diagnostic test accuracy research by ensuring all enrolled patients undergo both imaging modalities being compared in random order and regardless of the findings on either modality. • More studies are needed that directly compare the diagnostic performance of MRI and CT for PDAC staging after neoadjuvant therapy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Jajodia A, Wang A, Alabousi M, et al. MRI vs. CT for pancreatic adenocarcinoma vascular invasion: comparative diagnostic test accuracy systematic review and meta-analysis. Eur Radiol. 2023. PMID: 37083741. doi:10.1007/s00330-023-09659-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。